Published in Int J Clin Exp Pathol on January 01, 2011
Epithelial ovarian cancer experimental models. Oncogene (2013) 1.23
Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc (2014) 1.12
TR3 modulates platinum resistance in ovarian cancer. Cancer Res (2013) 0.88
The promise and challenge of ovarian cancer models. Transl Cancer Res (2015) 0.82
Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer. Front Oncol (2014) 0.82
Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model. J Ovarian Res (2013) 0.80
Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget (2015) 0.77
Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer. J Ovarian Res (2015) 0.76
Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer. Mol Cancer (2015) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol (2007) 5.68
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Ovarian cancer. Annu Rev Pathol (2009) 4.92
Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol (2007) 3.94
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther (2011) 2.74
Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol (2010) 2.65
Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene (2009) 2.27
Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol (2008) 1.70
The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol (2007) 1.46
Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications. Int J Gynecol Pathol (2010) 1.26
Preliminary experience with subcutaneous human ovarian cortex transplantation in the NOD-SCID mouse. Biol Reprod (1999) 1.25
STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed) (2011) 1.23
Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia (2011) 1.17
Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol (1999) 1.09
A human ovarian carcinoma murine xenograft model useful for preclinical trials. Gynecol Oncol (2002) 0.98
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res (2003) 0.96
Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. Cancer (2008) 0.93
Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 0.90
Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient mice. Gynecol Oncol (2000) 0.84
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res (2008) 3.98
An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell (2013) 2.30
Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell (2010) 2.20
Telephone triage in Western Australia. Med J Aust (2002) 2.06
Inhibition of α-helix-mediated protein-protein interactions using designed molecules. Nat Chem (2013) 2.02
Gene expression profiling of intestinal epithelial cell maturation along the crypt-villus axis. Gastroenterology (2005) 1.93
Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res (2003) 1.91
Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases. Virchows Arch (2006) 1.57
Tubal origin of 'ovarian' low-grade serous carcinoma. Mod Pathol (2011) 1.48
Nodular histiocytic aggregates in the endometrium: a report of 7 cases. Int J Gynecol Pathol (2014) 1.45
Bovine TB and badger culling. Vet Rec (2012) 1.39
Knowledge translation for effective consumers. Phys Ther (2007) 1.37
Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol (2012) 1.34
Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res (2005) 1.26
The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol (2008) 1.26
Oligobenzamide proteomimetic inhibitors of the p53-hDM2 protein-protein interaction. Chem Commun (Camb) (2009) 1.24
Evaluation of NHMRC funded research completed in 1992, 1997 and 2003: gains in knowledge, health and wealth. Med J Aust (2006) 1.21
Pattern recognition of proteins based on an array of functionalized porphyrins. J Am Chem Soc (2006) 1.18
EPHB4 and survival of colorectal cancer patients. Cancer Res (2006) 1.17
Population-attributable risk estimates for risk factors associated with Campylobacter infection, australia. Emerg Infect Dis (2008) 1.16
Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Clin Cancer Res (2010) 1.12
Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. Mod Pathol (2008) 1.12
Substrate selectivity and sensitivity to inhibition by FK506 and cyclosporin A of calcineurin heterodimers composed of the alpha or beta catalytic subunit. Eur J Biochem (2002) 1.07
Committee Opinion No. 631: Endometrial Intraepithelial Neoplasia. Obstet Gynecol (2015) 1.07
The immunoconjugate "icon" targets aberrantly expressed endothelial tissue factor causing regression of endometriosis. Am J Pathol (2009) 1.06
N-alkylated oligoamide alpha-helical proteomimetics. Org Biomol Chem (2010) 1.06
A proposed model for endometrial serous carcinogenesis. Am J Surg Pathol (2011) 1.05
Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. Eur J Haematol (2008) 1.04
The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Res (2009) 1.04
Proteomic changes during intestinal cell maturation in vivo. J Proteomics (2008) 1.02
Adenoid basal lesions of the uterine cervix: evolving terminology and clinicopathological concepts. Diagn Pathol (2006) 1.02
Gastric mucosal calcinosis: clinicopathologic considerations. Adv Anat Pathol (2007) 1.02
Pattern-based detection of different proteins using an array of fluorescent protein surface receptors. J Am Chem Soc (2004) 1.01
Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology. Arch Pathol Lab Med (2011) 0.99
Cotyledonoid dissecting leiomyoma of the uterus: a review of clinical, pathological, and radiological features. Int J Surg Pathol (2012) 0.96
Clients' perspective on service quality for type 2 diabetes in Australia. Aust N Z J Public Health (2007) 0.96
Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. Leuk Res (2007) 0.96
Synthesis of functionalised aromatic oligamide rods. Org Biomol Chem (2007) 0.95
Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease. Am J Clin Pathol (2006) 0.95
Dioxin may promote inflammation-related development of endometriosis. Fertil Steril (2008) 0.94
Age dependent association of endometrial polyps with increased risk of cancer involvement. World J Surg Oncol (2005) 0.92
Selective and potent proteomimetic inhibitors of intracellular protein-protein interactions. Angew Chem Int Ed Engl (2015) 0.92
Diagnostic parameters to differentiate benign from malignant ovarian masses with contrast-enhanced transvaginal sonography. J Ultrasound Med (2009) 0.92
Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance. Mod Pathol (2009) 0.92
Development of the effective musculoskeletal consumer scale. J Rheumatol (2007) 0.91
Helix-mediated protein--protein interactions as targets for intervention using foldamers. Amino Acids (2011) 0.91
The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod Pathol (2013) 0.91
Customer quality in health care. Patient Educ Couns (2008) 0.91
Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas. Int J Clin Exp Pathol (2012) 0.91
Diagnostic utility of P63 and CD10 in distinguishing cutaneous spindle cell/sarcomatoid squamous cell carcinomas and atypical fibroxanthomas. Int J Clin Exp Pathol (2008) 0.91
Attributes and skills of an effective musculoskeletal consumer. J Rheumatol (2005) 0.91
Imaging the clear cell renal cell carcinoma proteome. J Urol (2012) 0.90
Selective protein-surface sensing using ruthenium(II) tris(bipyridine) complexes. Chemistry (2010) 0.90
Small-molecule proteomimetic inhibitors of the HIF-1α-p300 protein-protein interaction. Chembiochem (2014) 0.89
Customer quality and type 2 diabetes from the patients' perspective: a cross-sectional study. J Res Health Sci (2010) 0.89
Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. Am J Cancer Res (2013) 0.89
Targeted approaches for reducing inequities in chronic disease. Med J Aust (2003) 0.88
Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer. Gynecol Oncol (2012) 0.88
TR3 modulates platinum resistance in ovarian cancer. Cancer Res (2013) 0.88
Nuclear translocation of calcineurin Abeta but not calcineurin Aalpha by platelet-derived growth factor in rat aortic smooth muscle. Am J Physiol Cell Physiol (2007) 0.87
The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21. Cancer Biol Ther (2010) 0.86
Macrocyclic scaffolds derived from p-aminobenzoic acid. Chem Commun (Camb) (2007) 0.86
Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger. Int J Cancer (2011) 0.86
2-O-alkylated para-benzamide α-helix mimetics: the role of scaffold curvature. Org Biomol Chem (2012) 0.86
Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium. Am J Pathol (2009) 0.85
A case of extrauterine endometrial stromal sarcoma in the colon diagnosed three decades after hysterectomy for benign disease. Case Rep Obstet Gynecol (2013) 0.85
Microwave assisted solid phase synthesis of highly functionalized N-alkylated oligobenzamide α-helix mimetics. Bioorg Med Chem (2012) 0.85
Protein surface recognition using geometrically pure Ru(II) tris(bipyridine) derivatives. Chem Commun (Camb) (2010) 0.85
Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am J Surg Pathol (2014) 0.85
Environment-gene interactions in intestinal cancer. Eur J Cancer Prev (2002) 0.84
Mechanisms of disease pathogenesis in long QT syndrome type 5. Am J Physiol Cell Physiol (2009) 0.84
Photo-induced covalent cross-linking for the analysis of biomolecular interactions. Chem Soc Rev (2013) 0.84
Substituent control over dimerization affinity of triply hydrogen bonded heterodimers. Org Lett (2010) 0.84
Development and prevention of postsurgical adhesions in a chimeric mouse model of experimental endometriosis. Fertil Steril (2010) 0.84
Orthogonal functionalisation of α-helix mimetics. Org Biomol Chem (2014) 0.84
Solid-phase methodology for synthesis of O-alkylated aromatic oligoamide inhibitors of α-helix-mediated protein-protein interactions. Chemistry (2013) 0.84
Dedifferentiated Liposarcoma of the Retroperitoneum with Extensive Leiomyosarcomatous Differentiation and beta-Human Chorionic Gonadotropin Production. Sarcoma (2008) 0.83
Sonographic depiction of intratumoral vascularity with 2- and 3-dimensional color Doppler techniques. J Ultrasound Med (2005) 0.83
Modeling of arylamide helix mimetics in the p53 peptide binding site of hDM2 suggests parallel and anti-parallel conformations are both stable. PLoS One (2012) 0.83
Trifluoromethyldiazirine: an effective photo-induced cross-linking probe for exploring amyloid formation. Chem Commun (Camb) (2008) 0.83
Telephone-based psychiatry advice service for general practitioners. Med J Aust (2005) 0.83
Catalytic unfolding and proteolysis of cytochrome C induced by synthetic binding agents. J Am Chem Soc (2004) 0.83
Intracortical schwannoma of the femur. Skeletal Radiol (2013) 0.83
A 69-year-old woman with a vulvar lesion. Phyllodes tumor of the vulva. Arch Pathol Lab Med (2006) 0.83
Differential vimentin expression in ovarian and uterine corpus endometrioid adenocarcinomas: diagnostic utility in distinguishing double primaries from metastatic tumors. Int J Gynecol Pathol (2014) 0.82
Design, synthesis and binding studies of a novel quadruple ADDA hydrogen-bond array. Org Biomol Chem (2012) 0.82
Conformer-independent ureidoimidazole motifs--tools to probe conformational and tautomeric effects on the molecular recognition of triply hydrogen-bonded heterodimers. Chemistry (2011) 0.81
Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance. Hum Pathol (2013) 0.81
Papanicolaou test in the detection of high-grade cervical lesions: a re-evaluation based on cytohistologic non-correlation rates in 356 concurrently obtained samples. Int J Clin Exp Pathol (2008) 0.81
Responsiveness of the Effective Consumer Scale (EC-17). J Rheumatol (2009) 0.81
Monosubstituted alkenyl amino acids for peptide "stapling". Chem Commun (Camb) (2013) 0.80
Exploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologies. Mol Biosyst (2015) 0.80
Analysis of amyloid nanostructures using photo-cross-linking: in situ comparison of three widely used photo-cross-linkers. ACS Chem Biol (2014) 0.79
The mechanism of formation of amide-based interlocked compounds: prediction of a new rotaxane-forming motif. Chemistry (2004) 0.79
Intestinal epithelial-specific PTEN inactivation results in tumor formation. Am J Physiol Gastrointest Liver Physiol (2011) 0.79
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2012) 0.79